X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/15/2863205/16626/en/Zevra-Therapeutics-Presents-New-Data-on-the-Long-Term-Safety-and-Efficacy-of-Arimoclomol-as-a-Treatment-for-Niemann-Pick-Disease-Type-C-at-the-SIMD-45th-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/03/04/2839444/16626/en/Zevra-Therapeutics-Provides-FDA-Update-on-the-PDUFA-Action-Date-for-Arimoclomol-as-a-Treatment-for-Niemann-Pick-Disease-Type-C.html
https://www.globenewswire.com//news-release/2024/01/11/2808325/7281/en/FDA-Acceptance-of-Zevra-s-Arimoclomol-NDA-Filing-for-Niemann-Pick-Disease-Type-C-NPC-Results-in-XOMA-Making-a-1-Million-Milestone-Payment-to-LadRx.html
https://www.globenewswire.com//news-release/2024/01/08/2805329/16626/en/Zevra-Therapeutics-Receives-FDA-Acceptance-of-Resubmission-of-NDA-for-Arimoclomol-as-a-Treatment-for-Niemann-Pick-Disease-Type-C.html
https://www.globenewswire.com//news-release/2023/12/27/2801321/16626/en/Zevra-Therapeutics-Announces-Resubmission-of-Arimoclomol-New-Drug-Application-to-the-U-S-Food-and-Drug-Administration.html
https://www.globenewswire.com/news-release/2023/02/24/2615164/16626/en/Zevra-Therapeutics-Announces-Arimoclomol-Research-Featured-in-Two-Poster-Presentations-at-the-19th-Annual-WORLDSymposium-2023.html
https://www.globenewswire.com/news-release/2022/05/16/2443399/16626/en/KemPharm-Announces-Strategic-Acquisition-of-Arimoclomol-from-Orphazyme-Expanding-its-Rare-CNS-Diseases-Pipeline.html
https://www.globenewswire.com/news-release/2022/03/22/2407395/0/en/Orphazyme-announces-withdrawal-of-European-Marketing-Authorisation-Application-for-arimoclomol-for-the-treatment-of-Niemann-Pick-disease-type-C.html
https://www.biospace.com/article/releases/cytrx-comments-on-orphazyme-s-update-on-european-union-regulatory-review-of-arimoclomol-in-niemann-pick-disease-type-c/
https://www.globenewswire.com/news-release/2022/02/07/2379789/0/en/Orphazyme-to-present-additional-data-on-arimoclomol-s-mechanism-of-action-during-2022-Annual-WORLDSymposium.html
https://www.globenewswire.com/news-release/2021/06/28/2253542/0/en/Orphazyme-announces-restructuring-to-focus-resources-on-supporting-a-path-forward-for-arimoclomol-in-NPC.html
https://www.globenewswire.com/news-release/2021/06/28/2253570/0/en/Orphazyme-presents-36-month-data-supporting-durable-response-to-arimoclomol-during-Parseghian-Scientific-Conference-for-NPC-Research.html
https://www.businesswire.com/news/home/20201231005028/en/CytRx-Issues-Statement-Regarding-U.S.-Regulatory-Review-of-Arimoclomol-for-Niemann-Pick-Disease-Type-C
https://www.orphazyme.com/news-feed/2020/12/27/orphazyme-provides-regulatory-update-on-arimoclomol-for-npc#:~:text=Copenhagen%2C%20Denmark%20%E2%80%93%20December%2027%2C,period%20of%20the%20New%20Drug
https://www.orphazyme.com/news-feed/2020/12/27/orphazyme-provides-regulatory-update-on-arimoclomol-for-npc#:~:text=Copenhagen%2C%20Denmark%20%E2%80%93%20December%2027%2C,period%20of%20the%20New%20Drug
https://www.orphazyme.com/news-feed/2020/10/23/orphazyme-accelerates-arimoclomol-pre-launch-activities-and-updates-financial-outlook-for-2020#:~:text=Orphazyme%20expects%20to%20finish%202020,for%20NPC%2C%20with%20Priority%20Review.
https://www.biospace.com/article/releases/cytrx-highlights-orphazyme-s-receipt-of-fda-acceptance-and-priority-review-of-its-new-drug-application-for-arimoclomol-for-niemann-pick-disease-type-c/?s=74
https://endpts.com/nearly-two-years-after-their-narrow-phiii-failure-orphazyme-gets-speedy-look-at-the-fda/
https://www.prnewswire.com/news-releases/cytrx-corporation-highlights-significant-positive-events-from-its-two-licensed-drugs-arimoclomol-and-aldoxorubicin-300977445.html
http://www.globenewswire.com/news-release/2019/07/21/1885499/0/en/Orphazyme-to-prepare-for-filing-of-arimoclomol-in-US-for-Niemann-Pick-disease-Type-C-NPC.html
http://www.globenewswire.com/news-release/2019/07/18/1884352/0/en/Orphazyme-completes-enrollment-in-phase-3-trial-evaluating-arimoclomol-in-Amyotrophic-Lateral-Sclerosis.html
https://www.prnewswire.com/news-releases/cytrx-corporation-highlights-arimoclomol-licensee-orphazyme-as-to-prepare-regulatory-submission-in-europe-for-niemann-pick-disease-type-c-300870983.html
https://endpts.com/orphazyme-lead-drug-fails-both-main-goals-in-key-study-but-company-insists-the-results-are-positive/
Market Place
Share 
